Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in bladder cancer

H Ozen1

  • 1Department of Urology, Hacettepe University, Ankara, Turkey.

Current Opinion in Oncology
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

Bacille Calmette-Guérin (BCG) is the only intravesical therapy shown to reduce bladder cancer progression and improve survival. Cathepsin B inhibitors may enhance BCG efficacy by preventing tumor invasion.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A new adjacent tool in the management of clinical T1a solid renal masses.

Actas urologicas espanolas·2026
Same author

Neutrophil volume distribution width as a new marker in detecting inflammatory bowel disease activation.

International journal of laboratory hematology·2016
Same author

Successful outcome with second hematopoietic stem cell transplantation in a patient with IL-10R deficiency.

Bone marrow transplantation·2015
Same author

Is routine stenting necessary in pyeloplasty?

Pediatric surgery international·2013
Same author

Can p53, Ki-67 and bcl-2 predict biochemical failure after radical prostatectomy?

Indian journal of urology : IJU : journal of the Urological Society of India·2010
Same author

Pathological, biochemical and haematological investigations on the protective effect of alpha-lipoic acid in experimental aflatoxin toxicosis in chicks.

British poultry science·2010
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Urology
  • Cancer Research

Background:

  • Intravesical chemotherapy and immunotherapy aim to reduce recurrence and progression in bladder cancer.
  • Bacille Calmette-Guérin (BCG) is the sole agent proven to decrease progression and enhance survival.
  • BCG's mechanism involves sparing fibronectin fragments that stimulate tumor cell motility and invasion.

Purpose of the Study:

  • To evaluate the potential of cathepsin B inhibitors in preventing bladder cancer progression.
  • To explore the combination of cathepsin B inhibitors with BCG for enhanced therapeutic outcomes.

Main Methods:

  • Review of in vivo and in vitro studies on cathepsin B inhibitors and their effect on basement membrane laminin degradation.
  • Analysis of clinical studies on BCG efficacy, including second-course treatments and adjuvant chemotherapy.

Related Experiment Videos

Main Results:

  • Cathepsin B inhibitors prevent the degradation of human basement membrane laminin, a crucial step in tumor invasion.
  • BCG's mechanism involves selective fibronectin degradation, potentially enhancing tumor invasion.
  • Second-course BCG and adjuvant chemotherapy have shown benefits in progression-free survival for specific patient groups.

Conclusions:

  • Cathepsin B inhibitors, alone or with BCG, show promise for preventing superficial bladder tumor progression.
  • Further controlled studies are needed to confirm the role of adjuvant chemotherapy.
  • Advancements in molecular genetics are continually refining our understanding of bladder cancer behavior.